RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.

RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.

Item
http://www.wikidata.org/entity/Q37625447
Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the VasculatureChronic kidney disease and osteoporosis: evaluation and management.Insights into aortic sclerosis and its relationship with coronary artery diseaseUpdate on denosumab treatment in postmenopausal women with osteoporosis.Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis.Management of severe osteoporosis.Lower leg arterial calcification assessed by high-resolution peripheral quantitative computed tomography is associated with bone microstructure abnormalities in women.Denosumab: a review of its use in postmenopausal women with osteoporosis.Osteoporosis and cardiovascular disease: an update.Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification.Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.Cortical bone laminar analysis reveals increased midcortical and periosteal porosity in type 2 diabetic postmenopausal women with history of fragility fractures compared to fracture-free diabetics.Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies.Association of Circulating Wnt Antagonists With Severe Abdominal Aortic Calcification in Elderly Women.Circulating osteogenic proteins are associated with coronary artery calcification and increase after myocardial infarction
P2860

RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.

Item
http://www.wikidata.org/entity/Q37625447
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RANKL inhibition with denosuma ...... and high cardiovascular risk.
@en
RANKL inhibition with denosuma ...... and high cardiovascular risk.
@nl
type
label
RANKL inhibition with denosuma ...... and high cardiovascular risk.
@en
RANKL inhibition with denosuma ...... and high cardiovascular risk.
@nl
prefLabel
RANKL inhibition with denosuma ...... and high cardiovascular risk.
@en
RANKL inhibition with denosuma ...... and high cardiovascular risk.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
RANKL inhibition with denosuma ...... and high cardiovascular risk.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932